Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders

Anu Jacob, Andrew B McKeon, Ichiro Nakashima, Douglas Kazutoshi Sato, Liene Elsone, Kazuo Fujihara, Jerome De Seze

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Neuromyelitis optica (NMO) has been described as a disease clinically characterised by severe optic neuritis (ON) and transverse myelitis (TM). Other features of NMO include female preponderance, longitudinally extensive spinal cord lesions (>3 vertebral segments), and absence of oligoclonal IgG bands . In spite of these differences from multiple sclerosis (MS), the relationship between NMO and MS has long been controversial. However, since the discovery of NMO-IgG or aquaporin-4 (AQP4) antibody (AQP4-antibody), an NMO-specific autoantibody to AQP4, the dominant water channel in the central nervous system densely expressed on end-feet of astrocytes, unique clinical features, MRI and other laboratory findings in NMO have been clarified further. AQP4-antibody is now the most important laboratory finding for the diagnosis of NMO. Apart from NMO, some patients with recurrent ON or recurrent longitudinally extensive myelitis alone are also often positive for AQP4-antibody. Moreover, studies of AQP4-antibody-positive patients have revealed that brain lesions are not uncommon in NMO, and some patterns appear to be unique to NMO. Thus, the spectrum of NMO is wider than mere ON and TM. Pathological analyses of autopsied cases strongly suggest that unlike MS, astrocytic damage is the primary pathology in NMO, and experimental studies confirm the pathogenicity of AQP4-antibody. Importantly, therapeutic outcomes of some immunological treatments are different between NMO and MS, making early differential diagnosis of these two disorders crucial. We provide an overview of the epidemiology, clinical and neuroimaging features, immunopathology and therapy of NMO and NMO spectrum disorders.

Original languageEnglish (US)
Pages (from-to)922-930
Number of pages9
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume84
Issue number8
DOIs
StatePublished - 2013

Fingerprint

Neuromyelitis Optica
Aquaporin 4
Optic Neuritis
Multiple Sclerosis
Antibodies
Transverse Myelitis
Oligoclonal Bands
Optics
Myelitis
Aquaporins
Clinical Laboratory Techniques
Transverse

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery
  • Arts and Humanities (miscellaneous)

Cite this

Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. / Jacob, Anu; McKeon, Andrew B; Nakashima, Ichiro; Sato, Douglas Kazutoshi; Elsone, Liene; Fujihara, Kazuo; De Seze, Jerome.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 84, No. 8, 2013, p. 922-930.

Research output: Contribution to journalArticle

Jacob, Anu ; McKeon, Andrew B ; Nakashima, Ichiro ; Sato, Douglas Kazutoshi ; Elsone, Liene ; Fujihara, Kazuo ; De Seze, Jerome. / Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. In: Journal of Neurology, Neurosurgery and Psychiatry. 2013 ; Vol. 84, No. 8. pp. 922-930.
@article{84851c4b65de4f7191faba4181b6d57a,
title = "Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders",
abstract = "Neuromyelitis optica (NMO) has been described as a disease clinically characterised by severe optic neuritis (ON) and transverse myelitis (TM). Other features of NMO include female preponderance, longitudinally extensive spinal cord lesions (>3 vertebral segments), and absence of oligoclonal IgG bands . In spite of these differences from multiple sclerosis (MS), the relationship between NMO and MS has long been controversial. However, since the discovery of NMO-IgG or aquaporin-4 (AQP4) antibody (AQP4-antibody), an NMO-specific autoantibody to AQP4, the dominant water channel in the central nervous system densely expressed on end-feet of astrocytes, unique clinical features, MRI and other laboratory findings in NMO have been clarified further. AQP4-antibody is now the most important laboratory finding for the diagnosis of NMO. Apart from NMO, some patients with recurrent ON or recurrent longitudinally extensive myelitis alone are also often positive for AQP4-antibody. Moreover, studies of AQP4-antibody-positive patients have revealed that brain lesions are not uncommon in NMO, and some patterns appear to be unique to NMO. Thus, the spectrum of NMO is wider than mere ON and TM. Pathological analyses of autopsied cases strongly suggest that unlike MS, astrocytic damage is the primary pathology in NMO, and experimental studies confirm the pathogenicity of AQP4-antibody. Importantly, therapeutic outcomes of some immunological treatments are different between NMO and MS, making early differential diagnosis of these two disorders crucial. We provide an overview of the epidemiology, clinical and neuroimaging features, immunopathology and therapy of NMO and NMO spectrum disorders.",
author = "Anu Jacob and McKeon, {Andrew B} and Ichiro Nakashima and Sato, {Douglas Kazutoshi} and Liene Elsone and Kazuo Fujihara and {De Seze}, Jerome",
year = "2013",
doi = "10.1136/jnnp-2012-302310",
language = "English (US)",
volume = "84",
pages = "922--930",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders

AU - Jacob, Anu

AU - McKeon, Andrew B

AU - Nakashima, Ichiro

AU - Sato, Douglas Kazutoshi

AU - Elsone, Liene

AU - Fujihara, Kazuo

AU - De Seze, Jerome

PY - 2013

Y1 - 2013

N2 - Neuromyelitis optica (NMO) has been described as a disease clinically characterised by severe optic neuritis (ON) and transverse myelitis (TM). Other features of NMO include female preponderance, longitudinally extensive spinal cord lesions (>3 vertebral segments), and absence of oligoclonal IgG bands . In spite of these differences from multiple sclerosis (MS), the relationship between NMO and MS has long been controversial. However, since the discovery of NMO-IgG or aquaporin-4 (AQP4) antibody (AQP4-antibody), an NMO-specific autoantibody to AQP4, the dominant water channel in the central nervous system densely expressed on end-feet of astrocytes, unique clinical features, MRI and other laboratory findings in NMO have been clarified further. AQP4-antibody is now the most important laboratory finding for the diagnosis of NMO. Apart from NMO, some patients with recurrent ON or recurrent longitudinally extensive myelitis alone are also often positive for AQP4-antibody. Moreover, studies of AQP4-antibody-positive patients have revealed that brain lesions are not uncommon in NMO, and some patterns appear to be unique to NMO. Thus, the spectrum of NMO is wider than mere ON and TM. Pathological analyses of autopsied cases strongly suggest that unlike MS, astrocytic damage is the primary pathology in NMO, and experimental studies confirm the pathogenicity of AQP4-antibody. Importantly, therapeutic outcomes of some immunological treatments are different between NMO and MS, making early differential diagnosis of these two disorders crucial. We provide an overview of the epidemiology, clinical and neuroimaging features, immunopathology and therapy of NMO and NMO spectrum disorders.

AB - Neuromyelitis optica (NMO) has been described as a disease clinically characterised by severe optic neuritis (ON) and transverse myelitis (TM). Other features of NMO include female preponderance, longitudinally extensive spinal cord lesions (>3 vertebral segments), and absence of oligoclonal IgG bands . In spite of these differences from multiple sclerosis (MS), the relationship between NMO and MS has long been controversial. However, since the discovery of NMO-IgG or aquaporin-4 (AQP4) antibody (AQP4-antibody), an NMO-specific autoantibody to AQP4, the dominant water channel in the central nervous system densely expressed on end-feet of astrocytes, unique clinical features, MRI and other laboratory findings in NMO have been clarified further. AQP4-antibody is now the most important laboratory finding for the diagnosis of NMO. Apart from NMO, some patients with recurrent ON or recurrent longitudinally extensive myelitis alone are also often positive for AQP4-antibody. Moreover, studies of AQP4-antibody-positive patients have revealed that brain lesions are not uncommon in NMO, and some patterns appear to be unique to NMO. Thus, the spectrum of NMO is wider than mere ON and TM. Pathological analyses of autopsied cases strongly suggest that unlike MS, astrocytic damage is the primary pathology in NMO, and experimental studies confirm the pathogenicity of AQP4-antibody. Importantly, therapeutic outcomes of some immunological treatments are different between NMO and MS, making early differential diagnosis of these two disorders crucial. We provide an overview of the epidemiology, clinical and neuroimaging features, immunopathology and therapy of NMO and NMO spectrum disorders.

UR - http://www.scopus.com/inward/record.url?scp=84879983472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879983472&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2012-302310

DO - 10.1136/jnnp-2012-302310

M3 - Article

VL - 84

SP - 922

EP - 930

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 8

ER -